BioEclipse Therapeutics announced today it has been awarded a $7,999,689.00 grant by the California Institute for Regenerative Medicine (CIRM) to support its ongoing clinical study: A Phase 1, open-label, dose-escalation study of CRX100 in patients with advanced solid tumors....
BioEclipse Therapeutics™ today announced today the appointment of Mahmoud Mahmoudian, Ph.D., FRSC, to the BioEclipse Board of Directors. Dr. Mahmoudian, an industry veteran who served as a senior executive at Sumitomo Dainippon Pharma Oncology (Sumitomo Oncology), brings with him decades of industry experience spanning venture investing, business development, and identifying, incubating, and developing novel...
Best StartUp - This article showcases our top picks for the best San Francisco based Therapeutics companies. These startups and companies are taking a variety of approaches to innovating the Therapeutics industry, but are all exceptional companies well worth a follow. We tried to pick companies across the size spectrum from cutting...
StartUp Insights - Global Startup Heat Map highlights 5 Top Startups tackling Ovarian Cancer out of 140 The insights of this data-driven analysis are derived from the Big Data & Artificial Intelligence-powered StartUs Insights Discovery Platform, covering 2.093.000+ startups & scaleups globally. The platform gives you an exhaustive overview of emerging technologies &...